Literature DB >> 786867

Inhibition of B lymphocyte activation by interaction with Fc receptors.

J L Ryan, P A Henkart.   

Abstract

Much early work indicated that specific antibody can play an inhibitory role in the immune response. This inhibitory activity was found to be dependent on an intact Fc portion of the antibody used, both in vivo and in vitro. Thus a role for lymphocyte Fc receptors in regulations of the immune response was suggested. However, soluble antigen-antibody complexes, which bind to Fc receptors, do not appear to inhibit B cell activation. Recent experiments have demonstrated that antigen-antibody complexes immobilized on a surface strikingly inhibit LPS induced B cell mitogenesis and polyclonal antibody synthesis. Mechanisms for Fc receptor-mediated inhibition of B cell activation have been considered, and a model proposed to explain many of these findings as well as allow for antigen specific inhibition.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 786867     DOI: 10.3109/08820137609033860

Source DB:  PubMed          Journal:  Immunol Commun        ISSN: 0090-0877


  7 in total

1.  The heterogeneity of Fc receptors on human peripheral mononuclear blood cells.

Authors:  M Sándor; G Füst; G A Medgyesi; A Erdei; J Gergely
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

2.  Immune complexes: biochemical and biological aspects.

Authors:  P Seth
Journal:  Indian J Pediatr       Date:  1983 Sep-Oct       Impact factor: 1.967

3.  Suppressive B-cell factor (SBF) produced by FcR-bearing B cells; suppression of B, but not non-B-cell proliferation.

Authors:  T Suzuki; M Miyama-Inaba; T Masuda; H Uchino; A Murakami; H Tanaka
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

4.  Isolation and characterization of Fc-receptors shed from human peripheral mononuclear cells.

Authors:  M Sándor; G Füst; G A Medgyesi; J Gergely
Journal:  Immunology       Date:  1978-09       Impact factor: 7.397

5.  Monoclonal SBF produced by a hybridoma: in-vitro and in-vivo suppression of B tumour-cell proliferation.

Authors:  T Suzuki; M Miyama-Inaba; T Masuda; H Uchino; K Ishii
Journal:  Immunology       Date:  1983-12       Impact factor: 7.397

6.  Protein A-binding immunosuppressive mouse serum factors.

Authors:  W A Cafruny; D Senitzer
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions.

Authors:  H H Sedlacek
Journal:  Klin Wochenschr       Date:  1980-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.